In terms of treatment patterns and efficacy, the biologic agents administered most often in our cohort were TNF inhibitors, reflecting their status among the prioritized biologic agents for the treatment of psoriasis by Clalit Health Services. This evidence concerns the gene TNF and psoriasis.